Skip to main content
Black Health logo Black Health

At-home lab tests review

Everlywell review for Black patients (2026)

4.3/5

Everlywell is the most comprehensive at-home lab platform for Black patients, with sickle cell trait, hemoglobin A1C, hormone panels, and HIV testing all available without a doctor visit. Results are physician-reviewed.

Last reviewed How we review

Pros and cons

Pros

  • Sickle cell trait screening at home; important for family planning in Black families with HbS history.
  • Hemoglobin A1C tracking without a clinic trip; useful for prediabetes monitoring or established diabetes.
  • Hormone panels (testosterone, estradiol, progesterone, DHEA, cortisol) for menopause, PCOS, or fertility workup.
  • HIV, syphilis, chlamydia, gonorrhea, and herpes panels; discreet shipping and physician-reviewed results.
  • Physician-signed lab orders are real; results can be shared with your in-person clinician.

Cons

  • Self-pay pricing adds up for patients who need multiple panels.
  • Phlebotomy quality (finger prick + capillary blood) is lower than venous draw for some tests; severely abnormal results require confirmatory in-lab testing.
  • Telehealth follow-up is offered for some results but is not as deep as an established clinician relationship.
  • Medicaid is not accepted; low-income Black patients who would benefit most have the highest cost barrier.

Pricing and coverage

Pricing
Single tests $49-$199; subscription bundles available. HSA / FSA eligible. Some insurance accepted for specific tests.
Insurance
Accepts commercial insurance
Notes
Select tests accept insurance reimbursement (women's health panel, food sensitivity, thyroid). Most at-home test kits are self-pay. HSA / FSA cards work for nearly all tests. Medicaid is not accepted directly.

Why at-home testing matters for Black patients

Several Black-prevalent conditions require regular monitoring or one-time screening that current US healthcare delivers inconsistently: sickle cell trait screening for family planning, hemoglobin A1C for the highest-prevalence diabetes population in the country, and STI screening including HIV for the populations with the highest new-infection rates. At-home testing routes around the clinic-access bottleneck and the documented bias in some primary-care testing patterns.

What Everlywell does well

Test menu breadth and operational reliability. Everlywell is the largest direct-to-consumer at-home lab provider in the US, with the broadest test menu including sickle cell trait (a test that is non-trivial to get from many primary-care doctors), hemoglobin A1C, full hormone panels, and STI panels. Results are physician-reviewed and you can request telehealth follow-up for abnormal results.

What to verify before ordering

Test method matters: some Everlywell tests use finger-prick capillary blood (less accurate at low concentrations than venous blood) and others use saliva or urine. For diagnostic decisions about insulin starts, hormone replacement therapy initiation, or surgical clearance, a confirmatory in-lab venous draw is the appropriate next step after an abnormal at-home result. For monitoring (an already-diagnosed condition you are tracking), at-home is usually adequate.

Sickle cell trait specifically

About 1 in 13 Black Americans carries sickle cell trait. Knowing your status is relevant for family planning, athletic training under extreme conditions, and altitude exposure. Many adults never get screened because newborn screening results from decades ago are lost. Everlywell's HbS screening is a one-time $89 test that gives you a permanent answer.

Our methodology

Evaluated against LetsGetChecked, Imaware, myLAB Box, and Quest Direct on test menu breadth, sickle-cell-trait inclusion, physician-review quality, and cost. October 2026.

Was this helpful?

Your feedback shapes what we cover next.

Thanks for letting us know.

If you found this useful, sign up for our newsletter to get more like this.

Thanks. What was missing?

Optional. We read every response.

Thanks.

We use this to prioritize the next round of edits.